Trial Outcomes & Findings for Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (NCT NCT00459706)

NCT ID: NCT00459706

Last Updated: 2013-03-28

Results Overview

Participant's response to the question "How satisfied are you with your injection device?" scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher score indicated greater satisfaction with the delivery mechanism.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

640 participants

Primary outcome timeframe

Day 84

Results posted on

2013-03-28

Participant Flow

Participant milestones

Participant milestones
Measure
Enbrel 50 mg Autoinjector
Enbrel 50 milligram (mg) once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Overall Study
STARTED
325
315
Overall Study
MODIFIED INTENT-TO-TREAT POPULATION
324
313
Overall Study
COMPLETED
299
294
Overall Study
NOT COMPLETED
26
21

Reasons for withdrawal

Reasons for withdrawal
Measure
Enbrel 50 mg Autoinjector
Enbrel 50 milligram (mg) once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Overall Study
Adverse Event
19
13
Overall Study
Withdrawal by Subject
1
6
Overall Study
Physician Decision
2
0
Overall Study
Discontinuation of Study by Sponsor
1
0
Overall Study
Protocol Violation
2
1
Overall Study
Failed to Return
1
0
Overall Study
Other
0
1

Baseline Characteristics

Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Enbrel 50 mg Autoinjector
n=325 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=315 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Total
n=640 Participants
Total of all reporting groups
Age Continuous
54.7 years
STANDARD_DEVIATION 12.9 • n=99 Participants
54.8 years
STANDARD_DEVIATION 12.9 • n=107 Participants
54.7 years
STANDARD_DEVIATION 12.9 • n=206 Participants
Sex/Gender, Customized
Male
85 participants
n=99 Participants
78 participants
n=107 Participants
163 participants
n=206 Participants
Sex/Gender, Customized
Female
240 participants
n=99 Participants
237 participants
n=107 Participants
477 participants
n=206 Participants

PRIMARY outcome

Timeframe: Day 84

Population: Modified Intent-to-Treat (mITT): All randomized participants who received at least 1 injection of test article and had at least 1 available evaluation after the first administration of test article. Number of participants analyzed (N) = participants with evaluable data.

Participant's response to the question "How satisfied are you with your injection device?" scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher score indicated greater satisfaction with the delivery mechanism.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=306 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=300 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction on Day 84 for 2 Different Delivery Mechanisms for Etanercept, Modified Intent-to-treat Population
8.3 units on a scale
Standard Deviation 2.4
7.2 units on a scale
Standard Deviation 2.6

PRIMARY outcome

Timeframe: Day 84

Population: Per-protocol (PP): mITT participants who completed the study with no major protocol violation. N=participants with evaluable data.

Participant's response to the question "How satisfied are you with your injection device?" scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher score indicated greater satisfaction with the delivery mechanism.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=292 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=281 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction on Day 84 for 2 Different Delivery Mechanisms for Etanercept, Per-Protocol Population
8.4 units on a scale
Standard Deviation 2.2
7.2 units on a scale
Standard Deviation 2.6

SECONDARY outcome

Timeframe: Day 28

Population: mITT. N=participants with evaluable data.

Percentage of participants answering "Yes" to the question "Are you satisfied with your injection device?"

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=297 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants on Day 28 Satisfied With Either of the Different Delivery Mechanisms for Etanercept
92.7 percentage of participants
88.6 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants answering "Yes" to the question "Are you satisfied with your injection device?"

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=297 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=284 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants on Day 84 Satisfied With Either of the Delivery Mechanisms for Etanercept
93.3 percentage of participants
87.7 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT; last observation carried forward (LOCF).

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction with the delivery mechanism. Results are reported by age categories: \<=46 years, \>46-55 years, \>55-65 years, \>65 years.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by Age for 2 Different Delivery Mechanisms for Etanercept
<=46 years
8.18 units on a scale
Standard Deviation 2.52
6.58 units on a scale
Standard Deviation 2.73
Participant Satisfaction by Age for 2 Different Delivery Mechanisms for Etanercept
>46 - 55 years
8.81 units on a scale
Standard Deviation 1.84
7.01 units on a scale
Standard Deviation 2.70
Participant Satisfaction by Age for 2 Different Delivery Mechanisms for Etanercept
>55 - 65 years
8.31 units on a scale
Standard Deviation 2.44
7.56 units on a scale
Standard Deviation 2.57
Participant Satisfaction by Age for 2 Different Delivery Mechanisms for Etanercept
>65 years
7.74 units on a scale
Standard Deviation 2.54
7.63 units on a scale
Standard Deviation 2.28

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF. N=total evaluable participants. n=participants evaluable in that category.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction with the delivery mechanism.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by Gender for 2 Different Delivery Mechanisms for Etanercept
Male (n=85, 77)
8.45 units on a scale
Standard Deviation 2.31
8.13 units on a scale
Standard Deviation 2.07
Participant Satisfaction by Gender for 2 Different Delivery Mechanisms for Etanercept
Female (n=239, 236)
8.21 units on a scale
Standard Deviation 2.40
6.89 units on a scale
Standard Deviation 2.72

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF. N=total participants with evaluable data. n=participants with evaluable data for that category.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction with the delivery mechanism. Participants were categorized into those having only reading/writing capacity, those at the high-school/baccalaureate level, and those at the university level.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=323 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=311 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by Socio-Educational Level for 2 Different Delivery Mechanisms for Etanercept
Only Reading/Writing Capacity (n=122, 129)
8.11 units on a scale
Standard Deviation 2.24
7.53 units on a scale
Standard Deviation 2.44
Participant Satisfaction by Socio-Educational Level for 2 Different Delivery Mechanisms for Etanercept
High School/Baccalaureate Level (n=147, 136)
8.32 units on a scale
Standard Deviation 2.50
6.90 units on a scale
Standard Deviation 2.87
Participant Satisfaction by Socio-Educational Level for 2 Different Delivery Mechanisms for Etanercept
University Level (n=54, 46)
8.44 units on a scale
Standard Deviation 2.36
7.09 units on a scale
Standard Deviation 2.38

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction with the delivery mechanism. The HAD scale assessed participants' levels of anxiety and depression over the past week; total 14 questions, odd-numbered questions related to anxiety. Responses scored on a 4-point scale; each question was graded in a different way. Anxiety subscale scores ranged from 0 to 21. Lower HAD Anxiety subscale scores indicated better health. Categories are anxiety subscale scores.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by the Hospital Anxiety Depression (HAD) Anxiety Subscale Score for 2 Different Delivery Mechanisms for Etanercept
HAD anxiety subscale score <=4
8.56 units on a scale
Standard Deviation 2.29
7.67 units on a scale
Standard Deviation 2.44
Participant Satisfaction by the Hospital Anxiety Depression (HAD) Anxiety Subscale Score for 2 Different Delivery Mechanisms for Etanercept
HAD anxiety subscale score >4 - 7
8.13 units on a scale
Standard Deviation 2.47
7.32 units on a scale
Standard Deviation 2.56
Participant Satisfaction by the Hospital Anxiety Depression (HAD) Anxiety Subscale Score for 2 Different Delivery Mechanisms for Etanercept
HAD anxiety subscale score >7 - 10
7.87 units on a scale
Standard Deviation 2.68
6.93 units on a scale
Standard Deviation 2.53
Participant Satisfaction by the Hospital Anxiety Depression (HAD) Anxiety Subscale Score for 2 Different Delivery Mechanisms for Etanercept
HAD anxiety subscale score >10
8.46 units on a scale
Standard Deviation 2.06
6.67 units on a scale
Standard Deviation 2.97

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction with the delivery mechanism. The HAD scale assessed participants' levels of anxiety and depression over the past week; total 14 questions, even-numbered questions related to depression. Responses scored on a 4-point scale; each question was graded in a different way. Depression subscale scores ranged from 0 to 21. Lower HAD Depression subscale scores indicated better health. Categories are depression subscale scores.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by the HAD Depression Subscale Score for 2 Different Delivery Mechanisms for Etanercept
HAD depression subscale score <=3
8.75 units on a scale
Standard Deviation 2.02
7.70 units on a scale
Standard Deviation 2.37
Participant Satisfaction by the HAD Depression Subscale Score for 2 Different Delivery Mechanisms for Etanercept
HAD depression subscale score >3 - 5
7.97 units on a scale
Standard Deviation 2.58
7.35 units on a scale
Standard Deviation 2.66
Participant Satisfaction by the HAD Depression Subscale Score for 2 Different Delivery Mechanisms for Etanercept
HAD depression subscale score >5 - 8.2
8.28 units on a scale
Standard Deviation 2.39
7.17 units on a scale
Standard Deviation 2.49
Participant Satisfaction by the HAD Depression Subscale Score for 2 Different Delivery Mechanisms for Etanercept
HAD depression subscale score >8.2
8.03 units on a scale
Standard Deviation 2.48
6.23 units on a scale
Standard Deviation 2.94

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction for the delivery mechanism. The 13-item short form of the PAM survey assessed participants' knowledge, skill, and confidence for self-management; calibrated scale score ranged from 0 to 100. Higher scores indicated more confidence in managing participants' condition and lifestyle. Results reported by PAM score: \<=49.9, \>49.9-56.4, \>56.4-66, \>66.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by Patient Activation Measure (PAM) Score for 2 Different Delivery Mechanisms for Etanercept
PAM scale score <=49.9
7.91 units on a scale
Standard Deviation 2.58
7.06 units on a scale
Standard Deviation 2.72
Participant Satisfaction by Patient Activation Measure (PAM) Score for 2 Different Delivery Mechanisms for Etanercept
PAM scale score >49.9 - 56.4
8.48 units on a scale
Standard Deviation 2.14
7.42 units on a scale
Standard Deviation 2.36
Participant Satisfaction by Patient Activation Measure (PAM) Score for 2 Different Delivery Mechanisms for Etanercept
PAM scale score >56.4 - 66
8.02 units on a scale
Standard Deviation 2.56
6.97 units on a scale
Standard Deviation 2.83
Participant Satisfaction by Patient Activation Measure (PAM) Score for 2 Different Delivery Mechanisms for Etanercept
PAM scale score >66
8.49 units on a scale
Standard Deviation 2.32
7.38 units on a scale
Standard Deviation 2.63

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF. N=total evaluable participants. n=evaluable participants for that category.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Participants were grouped into 2 categories: those who did and did not have prior self-injection experience. Higher scores indicated greater satisfaction in the delivery mechanism.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by Prior Self-Injection Experience for 2 Different Delivery Mechanisms for Etanercept
Self-Injection Experience (n=97, 101)
8.10 units on a scale
Standard Deviation 2.51
6.57 units on a scale
Standard Deviation 2.51
Participant Satisfaction by Prior Self-Injection Experience for 2 Different Delivery Mechanisms for Etanercept
No Self-Injection Experience (n=227, 212)
8.34 units on a scale
Standard Deviation 2.32
7.49 units on a scale
Standard Deviation 2.64

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction for the delivery mechanism. Results are reported by duration of RA: \<=3 years, \>3-6 years, \>6-13 years, \>13 years.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by Duration of Rheumatoid Arthritis (RA) for 2 Different Delivery Mechanisms for Etanercept
RA duration <=3 years
7.99 units on a scale
Standard Deviation 2.56
7.32 units on a scale
Standard Deviation 2.59
Participant Satisfaction by Duration of Rheumatoid Arthritis (RA) for 2 Different Delivery Mechanisms for Etanercept
RA duration >3 - 6 years
8.39 units on a scale
Standard Deviation 2.34
6.68 units on a scale
Standard Deviation 2.83
Participant Satisfaction by Duration of Rheumatoid Arthritis (RA) for 2 Different Delivery Mechanisms for Etanercept
RA duration >6 - 13 years
8.52 units on a scale
Standard Deviation 2.37
7.24 units on a scale
Standard Deviation 2.67
Participant Satisfaction by Duration of Rheumatoid Arthritis (RA) for 2 Different Delivery Mechanisms for Etanercept
RA duration >13 years
8.29 units on a scale
Standard Deviation 2.14
7.40 units on a scale
Standard Deviation 2.47

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction for the delivery mechanism. DAS28 includes a 28 tender joint count, a 28 swollen joint count, erythrocyte sedimentation rate, and a general health assessment on a visual analog scale. Score ranged from 0 to 9.4. Interpretation: disease activity is low when score ≤3.2, moderate when 3.2\<score≤5.1, or high when score \>5.1, remission when score \<2.6. Results are reported by categories of DAS28 score: \<=4.7, \>4.7-5.4, \>5.4-6.2, \>6.2.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by 28-joint Disease Activity Score (DAS28) for 2 Different Delivery Mechanisms for Etanercept
DAS28 score <=4.7
8.24 units on a scale
Standard Deviation 2.50
7.01 units on a scale
Standard Deviation 2.50
Participant Satisfaction by 28-joint Disease Activity Score (DAS28) for 2 Different Delivery Mechanisms for Etanercept
DAS28 score >4.7 - 5.4
8.11 units on a scale
Standard Deviation 2.59
7.36 units on a scale
Standard Deviation 2.64
Participant Satisfaction by 28-joint Disease Activity Score (DAS28) for 2 Different Delivery Mechanisms for Etanercept
DAS28 score >5.4 - 6.2
8.45 units on a scale
Standard Deviation 2.19
7.58 units on a scale
Standard Deviation 2.55
Participant Satisfaction by 28-joint Disease Activity Score (DAS28) for 2 Different Delivery Mechanisms for Etanercept
DAS28 score >6.2
8.31 units on a scale
Standard Deviation 2.23
6.90 units on a scale
Standard Deviation 2.85

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction for the delivery mechanism. Participants' global assessment of disease activity was measured on a visual analog scale (VAS) ranging from 0 (inactive) to 100 millimeter (mm) (extremely active). Results are reported by VAS scores observed for the participant's global assessment of RA activity: \<=50 mm, \>50-67 mm, \>67-79 mm, \>79 mm.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by Participant's Global Assessment of RA Activity for 2 Different Delivery Mechanisms for Etanercept
VAS score for participant's assessment <=50 mm
8.45 units on a scale
Standard Deviation 2.14
7.55 units on a scale
Standard Deviation 2.43
Participant Satisfaction by Participant's Global Assessment of RA Activity for 2 Different Delivery Mechanisms for Etanercept
VAS score for participant's assessment >50 - 67
8.41 units on a scale
Standard Deviation 2.15
7.31 units on a scale
Standard Deviation 2.61
Participant Satisfaction by Participant's Global Assessment of RA Activity for 2 Different Delivery Mechanisms for Etanercept
VAS score for participant's assessment >67 - 79 mm
8.07 units on a scale
Standard Deviation 2.60
7.11 units on a scale
Standard Deviation 2.53
Participant Satisfaction by Participant's Global Assessment of RA Activity for 2 Different Delivery Mechanisms for Etanercept
VAS score for participant's assessment >79 mm
8.17 units on a scale
Standard Deviation 2.59
6.88 units on a scale
Standard Deviation 2.83

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction with the delivery mechanism. Physicians' global assessment of disease activity was measured on a VAS ranging from 0 (inactive) to 100 mm (extremely active). Results are reported by VAS scores observed for physician's global assessment of RA activity: \<=47 mm, \>47-61 mm, \>61-72 mm, \>72 mm.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by Physician's Global Assessment of RA Activity for 2 Different Delivery Mechanisms for Etanercept
VAS score for physician's assessment <=47 mm
8.23 units on a scale
Standard Deviation 2.40
7.40 units on a scale
Standard Deviation 2.24
Participant Satisfaction by Physician's Global Assessment of RA Activity for 2 Different Delivery Mechanisms for Etanercept
VAS score for physician's assessment >47 - 61 mm
8.36 units on a scale
Standard Deviation 2.00
6.92 units on a scale
Standard Deviation 2.73
Participant Satisfaction by Physician's Global Assessment of RA Activity for 2 Different Delivery Mechanisms for Etanercept
VAS score for physician's assessment >61 - 72 mm
8.03 units on a scale
Standard Deviation 2.75
7.14 units on a scale
Standard Deviation 2.96
Participant Satisfaction by Physician's Global Assessment of RA Activity for 2 Different Delivery Mechanisms for Etanercept
VAS score for physician's assessment >72 mm
8.47 units on a scale
Standard Deviation 2.34
7.32 units on a scale
Standard Deviation 2.59

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction with the delivery mechanism. The 20-item HAQ-DI assessed the extent of participants' functional ability. Calculation yielded a single disability score from 0=normal or no difficulty to 3=unable to do. Lower HAQ-DI scores indicated better health. Results are reported by categories of HAQ-DI scores observed: \<=0.9, \>0.9-1.4, \>1.4-1.9, \>1.9.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by Health Assessment Questionnaire - Disability Index (HAQ-DI) for 2 Different Delivery Mechanisms for Etanercept
HAQ-DI scale score <=0.9
8.61 units on a scale
Standard Deviation 2.07
7.67 units on a scale
Standard Deviation 2.24
Participant Satisfaction by Health Assessment Questionnaire - Disability Index (HAQ-DI) for 2 Different Delivery Mechanisms for Etanercept
HAQ-DI scale score >0.9 - 1.4
8.27 units on a scale
Standard Deviation 2.37
7.40 units on a scale
Standard Deviation 2.39
Participant Satisfaction by Health Assessment Questionnaire - Disability Index (HAQ-DI) for 2 Different Delivery Mechanisms for Etanercept
HAQ-DI scale score >1.4 - 1.9
8.33 units on a scale
Standard Deviation 2.37
7.03 units on a scale
Standard Deviation 2.84
Participant Satisfaction by Health Assessment Questionnaire - Disability Index (HAQ-DI) for 2 Different Delivery Mechanisms for Etanercept
HAQ-DI scale score >1.9
7.96 units on a scale
Standard Deviation 2.58
6.57 units on a scale
Standard Deviation 2.95

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF. N=total evaluable participants. n=total evaluable participants for that category.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction for the delivery mechanism. Participants were categorized into those who received only 1 DMARD, only 2 DMARDs, only 3 DMARDs, and at least 3 DMARDs.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=320 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=311 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by Maximum Combination of Disease-Modifying Antirheumatic Drug (DMARD) Use for 2 Different Delivery Mechanisms for Etanercept
1 DMARD (n=177, 162)
8.29 units on a scale
Standard Deviation 2.41
7.23 units on a scale
Standard Deviation 2.66
Participant Satisfaction by Maximum Combination of Disease-Modifying Antirheumatic Drug (DMARD) Use for 2 Different Delivery Mechanisms for Etanercept
2 DMARDs (n=123, 123)
8.18 units on a scale
Standard Deviation 2.42
7.19 units on a scale
Standard Deviation 2.53
Participant Satisfaction by Maximum Combination of Disease-Modifying Antirheumatic Drug (DMARD) Use for 2 Different Delivery Mechanisms for Etanercept
3 DMARDs (n=16, 26)
8.94 units on a scale
Standard Deviation 1.84
6.85 units on a scale
Standard Deviation 3.04
Participant Satisfaction by Maximum Combination of Disease-Modifying Antirheumatic Drug (DMARD) Use for 2 Different Delivery Mechanisms for Etanercept
At Least 4 DMARDs (n=4, 0)
9.50 units on a scale
Standard Deviation 1.00
NA units on a scale
Standard Deviation NA
NA=not available. This category had no participants, hence no data are available.

SECONDARY outcome

Timeframe: Day 84

Population: mITT; LOCF. n=evaluable participants in that category.

Participant satisfaction scored on a 10-point ordinal scale: 0=totally dissatisfied to 10=totally satisfied. Participants were grouped into 2 categories: those who did and did not have prior injection experience. Higher scores indicated greater satisfaction with the delivery mechanism.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=324 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction by Prior Injection Experience for 2 Different Delivery Mechanisms for Etanercept
Prior Injection Experience (n=177, 174)
8.29 units on a scale
Standard Deviation 2.35
7.05 units on a scale
Standard Deviation 2.53
Participant Satisfaction by Prior Injection Experience for 2 Different Delivery Mechanisms for Etanercept
No Prior Injection Experience (n=147, 139)
8.24 units on a scale
Standard Deviation 2.42
7.37 units on a scale
Standard Deviation 2.75

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=number of evaluable participants.

The SF-STAI consisted of 6 questions, each scored from 1 to 4. Total score ranged from 6=less anxiety to 24=more anxiety. Higher score indicated that the participant was more anxious.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=303 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=298 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Short Form of the State-Trait Anxiety Inventory (SF-STAI) Global Score
10.0 units on a scale
Standard Deviation 3.7
10.5 units on a scale
Standard Deviation 3.4

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=number of evaluable participants.

Score indicated satisfaction in response to the question "Thinking about your own life and personal circumstances, how satisfied are you with your life as a whole?" Score ranged from 0=completely dissatisfied to 10=completely satisfied. Higher scores indicated greater satisfaction.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=307 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=300 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Device Attributes and Participant Perception Questionnaire: How Satisfied Is the Subject With His/Her Life as a Whole?
7.3 units on a scale
Standard Deviation 2.2
7.1 units on a scale
Standard Deviation 2.1

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=number of evaluable participants.

Score indicated satisfaction in response to the question "How satisfied are you with your health?" Score ranged from 0=completely dissatisfied to 10=completely satisfied. Higher scores indicated greater satisfaction.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=307 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Device Attributes and Participant Perception Questionnaire: How Satisfied Is the Subject With His/Her Health?
6.1 units on a scale
Standard Deviation 2.5
6.1 units on a scale
Standard Deviation 2.4

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=number of evaluable participants.

Score indicated satisfaction in response to the question "How satisfied are you with all the treatments you are currently receiving for your rheumatoid arthritis?" Score ranged from 0=completely dissatisfied to 10=completely satisfied. Higher scores indicated greater satisfaction.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=307 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Device Attributes and Participant Perception Questionnaire: How Satisfied Is the Subject With All the Treatments He/She is Currently Receiving for RA?
7.4 units on a scale
Standard Deviation 2.4
7.3 units on a scale
Standard Deviation 2.4

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Easy You Find the Device Is to Use - Q1: Overall, How Easy Was It to Perform an Injection with this Device? Participants specified their responses on a 5-point Likert scale: 0=very easy to 4=very difficult.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=298 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=295 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 1, Day 84
0=Very Easy
69.5 percentage of participants
54.2 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 1, Day 84
1=Easy
17.1 percentage of participants
26.1 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 1, Day 84
2=Neither Easy nor Difficult
7.0 percentage of participants
12.5 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 1, Day 84
3=Difficult
4.7 percentage of participants
5.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 1, Day 84
4=Very Difficult
1.7 percentage of participants
1.7 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Easy You Find the Device Is to Use - Q2: How Easy Was It to Learn to Use the Device? Participants specified their responses on a 5-point Likert scale: 0=very easy to 4=very difficult.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=295 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=294 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 2, Day 84
0=Very Easy
75.3 percentage of participants
62.9 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 2, Day 84
1=Easy
15.9 percentage of participants
30.6 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 2, Day 84
2=Neither Easy nor Difficult
5.4 percentage of participants
5.1 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 2, Day 84
3=Difficult
1.7 percentage of participants
1.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 2, Day 84
4=Very Difficult
1.7 percentage of participants
0.3 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Easy You Find the Device Is to Use - Q3: How Easy Is It to Dispose Of the Device? Participants specified their responses on a 5-point Likert scale: 0=very easy to 4=very difficult.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=288 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=291 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 3, Day 84
0=Very Easy
85.4 percentage of participants
74.9 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 3, Day 84
1=Easy
10.4 percentage of participants
19.2 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 3, Day 84
2=Neither Easy nor Difficult
2.4 percentage of participants
4.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 3, Day 84
3=Difficult
1.0 percentage of participants
1.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 3, Day 84
4=Very Difficult
0.7 percentage of participants
0.0 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Easy You Find the Device Is to Use - Q4: How Easy Is It to Know When the Injection Is Completed? Participants specified their responses on a 5-point Likert scale: 0=very easy to 4=very difficult.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=297 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=295 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 4, Day 84
0=Very Easy
81.1 percentage of participants
63.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 4, Day 84
1=Easy
13.1 percentage of participants
26.1 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 4, Day 84
2=Neither Easy nor Difficult
2.7 percentage of participants
7.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 4, Day 84
3=Difficult
2.7 percentage of participants
2.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 4, Day 84
4=Very Difficult
0.3 percentage of participants
0.3 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Easy You Find the Device Is to Use - Q5: How Easy Is It to Hold the Device Whilst Injecting? Participants specified their responses on a 5-point Likert scale: 0=very easy to 4=very difficult.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=292 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=294 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 5, Day 84
0=Very Easy
63.7 percentage of participants
47.3 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 5, Day 84
1=Easy
23.3 percentage of participants
26.9 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 5, Day 84
2=Neither Easy nor Difficult
7.9 percentage of participants
16.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 5, Day 84
3=Difficult
2.7 percentage of participants
7.1 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 5, Day 84
4=Very Difficult
2.4 percentage of participants
2.7 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Easy You Find the Device Is to Use - Q6: Did You Feel any Hand Discomfort Whilst Using the Device? Participants specified their responses on a 5-point Likert scale: 0=very easy to 4=very difficult.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=297 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=291 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 6, Day 84
3=Difficult
3.4 percentage of participants
7.6 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 6, Day 84
4=Very Difficult
1.3 percentage of participants
3.1 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 6, Day 84
0=Very Easy
69.0 percentage of participants
54.3 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 6, Day 84
1=Easy
18.5 percentage of participants
19.9 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 6, Day 84
2=Neither Easy nor Difficult
7.7 percentage of participants
15.1 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Easy You Find the Device Is to Use - Q7: How Long Does It Take to Perform the Injection, Including any Preparation and Disposal? Participants specified their responses on a 5-point Likert scale: 0=\<5 minutes to 4=\>30 minutes.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=295 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=295 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 7, Day 84
<5 minutes
64.7 percentage of participants
57.6 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 7, Day 84
5-10 minutes
22.0 percentage of participants
30.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 7, Day 84
11-20 minutes
6.8 percentage of participants
6.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 7, Day 84
21-30 minutes
5.1 percentage of participants
3.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 7, Day 84
>30 minutes
1.4 percentage of participants
1.0 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Convenient You Find the Device Is to Use - Q8: How Much Do You Think Injecting Etanercept Will Interfere with Your Ability to Enjoy Social or Leisure Activities? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=300 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 8, Day 84
0=Not at all
71.1 percentage of participants
64.3 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 8, Day 84
1=A little
14.3 percentage of participants
17.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 8, Day 84
2=Somewhat
7.0 percentage of participants
11.3 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 8, Day 84
3=A lot
4.7 percentage of participants
4.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 8, Day 84
4=Very much
3.0 percentage of participants
2.0 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Convenient You Find the Device Is to Use - Q9: Do You Think Injecting Etanercept Will Interfere with Your Usual Daily Activities? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=302 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=299 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 9, Day 84
0=Not at all
78.8 percentage of participants
73.2 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 9, Day 84
1=A little
12.3 percentage of participants
15.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 9, Day 84
2=Somewhat
5.6 percentage of participants
5.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 9, Day 84
3=A lot
2.3 percentage of participants
4.3 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 9, Day 84
4=Very much
1.0 percentage of participants
1.0 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Convenient You Find the Device Is to Use - Q10: How Much Do You Think Injecting Etanercept Will Interfere with Travelling on Holiday/ Business/Visiting? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=300 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 10, Day 84
0=Not at all
60.5 percentage of participants
48.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 10, Day 84
1=A little
20.6 percentage of participants
23.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 10, Day 84
2=Somewhat
9.3 percentage of participants
17.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 10, Day 84
3=A lot
7.0 percentage of participants
7.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 10, Day 84
4=Very much
2.7 percentage of participants
3.7 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Confident You Feel When Using the Device - Q11: Overall, How Confident Are You in Your Management of Your Weekly Injections? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=305 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=299 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 11, Day 84
0=Not at all
2.3 percentage of participants
2.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 11, Day 84
1=A little
1.6 percentage of participants
5.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 11, Day 84
2=Somewhat
6.2 percentage of participants
8.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 11, Day 84
3=A lot
22.0 percentage of participants
30.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 11, Day 84
4=Very much
67.9 percentage of participants
53.8 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Confident You Feel When Using the Device - Q12: How Confident Are You That You Inject the Right Amount of Medicine Every Time? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=305 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=300 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 12, Day 84
0=Not at all
1.3 percentage of participants
1.3 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 12, Day 84
1=A little
2.3 percentage of participants
5.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 12, Day 84
2=Somewhat
5.6 percentage of participants
7.3 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 12, Day 84
3=A lot
17.7 percentage of participants
21.3 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 12, Day 84
4=Very much
73.1 percentage of participants
65.0 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Confident You Feel When Using the Device - Q13: How Confident Are You That You Can Inject Yourself Properly with the Device? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=303 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=299 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 13, Day 84
0=Not at all
3.0 percentage of participants
1.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 13, Day 84
1=A little
3.0 percentage of participants
6.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 13, Day 84
2=Somewhat
5.9 percentage of participants
8.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 13, Day 84
3=A lot
17.2 percentage of participants
23.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 13, Day 84
4=Very much
71.0 percentage of participants
60.5 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Confident You Feel When Using the Device - Q14: Are You Confident That You Have Good Control over the Injection Process? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=305 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=299 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 14, Day 84
0=Not at all
2.3 percentage of participants
1.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 14, Day 84
1=A little
2.6 percentage of participants
4.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 14, Day 84
2=Somewhat
5.6 percentage of participants
7.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 14, Day 84
3=A lot
17.0 percentage of participants
25.1 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 14, Day 84
4=Very much
72.5 percentage of participants
61.5 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Confident You Feel When Using the Device - Q15: How Confident Are You That You Injected Yourself Successfully? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=304 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=299 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 15, Day 84
0=Not at all
2.6 percentage of participants
1.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 15, Day 84
1=A little
2.0 percentage of participants
3.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 15, Day 84
2=Somewhat
4.9 percentage of participants
8.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 15, Day 84
3=A lot
20.1 percentage of participants
25.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 15, Day 84
4=Very much
70.4 percentage of participants
60.9 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How You Feel When Using the Device - Q16: Overall, How Nervous Do You Feel about Your Injections? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=306 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=300 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 16, Day 84
0=Not at all
66.7 percentage of participants
49.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 16, Day 84
1=A little
19.3 percentage of participants
25.3 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 16, Day 84
2=Somewhat
8.8 percentage of participants
15.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 16, Day 84
3=A lot
3.6 percentage of participants
7.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 16, Day 84
4=Very much
1.6 percentage of participants
3.7 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How You Feel When Using the Device - Q17: Overall, How Nervous Do You Feel about Inserting the Needle into Your Skin? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=305 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=299 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 17, Day 84
0=Not at all
64.3 percentage of participants
45.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 17, Day 84
1=A little
21.3 percentage of participants
27.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 17, Day 84
2=Somewhat
6.9 percentage of participants
12.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 17, Day 84
3=A lot
5.9 percentage of participants
8.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 17, Day 84
4=Very much
1.6 percentage of participants
5.7 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How You Feel When Using the Device - Q18: Do You Dislike Injecting Yourself with this Device? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=305 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=300 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 18, Day 84
2=Somewhat
6.6 percentage of participants
14.3 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 18, Day 84
3=A lot
3.9 percentage of participants
9.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 18, Day 84
0=Not at all
70.8 percentage of participants
46.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 18, Day 84
1=A little
17.4 percentage of participants
22.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 18, Day 84
4=Very much
1.3 percentage of participants
8.0 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How You Feel When Using the Device - Q19: Overall, Are You Emotionally Distressed or Anxious about Your Injections? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=306 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=299 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 19, Day 84
3=A lot
2.3 percentage of participants
6.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 19, Day 84
0=Not at all
70.6 percentage of participants
57.2 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 19, Day 84
1=A little
18.0 percentage of participants
22.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 19, Day 84
2=Somewhat
7.2 percentage of participants
8.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 19, Day 84
4=Very much
2.0 percentage of participants
5.0 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: What Characteristics of the Device You Appreciate - Q20: How Much Do You Like the Look of the Device? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=304 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=298 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 20, Day 84
0=Not at all
1.6 percentage of participants
10.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 20, Day 84
1=A little
3.6 percentage of participants
10.1 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 20, Day 84
2=Somewhat
19.4 percentage of participants
35.9 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 20, Day 84
3=A lot
32.6 percentage of participants
24.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 20, Day 84
4=Very much
42.8 percentage of participants
18.8 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: What Characteristics of the Device You Appreciate - Q21: How Much Do You Like the Feel of the Device? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=304 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 21, Day 84
1=A little
3.0 percentage of participants
10.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 21, Day 84
0=Not at all
3.0 percentage of participants
9.5 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 21, Day 84
2=Somewhat
20.1 percentage of participants
35.1 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 21, Day 84
3=A lot
33.6 percentage of participants
27.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 21, Day 84
4=Very much
40.5 percentage of participants
17.6 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: What Characteristics of the Device You Appreciate - Q22: How Much Does the Device Look Like Something You Would Feel Comfortable to Use? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=302 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=297 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 22, Day 84
0=Not at all
4.0 percentage of participants
12.1 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 22, Day 84
1=A little
3.6 percentage of participants
8.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 22, Day 84
2=Somewhat
18.2 percentage of participants
31.6 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 22, Day 84
3=A lot
27.5 percentage of participants
29.0 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 22, Day 84
4=Very much
46.7 percentage of participants
18.5 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: Side Effects from Using the Device - Q23: Do You Experience Pain During or Immediately After the Injection? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=304 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=298 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 23, Day 84
1=A little
28.0 percentage of participants
29.9 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 23, Day 84
4=Very much
3.6 percentage of participants
3.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 23, Day 84
0=Not at all
36.2 percentage of participants
39.6 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 23, Day 84
2=Somewhat
20.4 percentage of participants
17.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 23, Day 84
3=A lot
11.8 percentage of participants
9.1 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Likely Is It That You Would Use the Device Again - Q24: To What Extent Would You Consider Alternative Devices If You Were to Continue on Etanercept? Participants specified their responses on a 5-point Likert scale: 0=very little to 4=very much.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=240 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=232 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 24, Day 84
0=Very little
48.8 percentage of participants
28.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 24, Day 84
1=A little
8.8 percentage of participants
21.1 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 24, Day 84
2=Somewhat
20.8 percentage of participants
22.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 24, Day 84
3=A lot
8.3 percentage of participants
11.2 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 24, Day 84
4=Very much
13.3 percentage of participants
16.4 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Likely Is It That You Would Use the Device Again - Q25: Would You Recommend this Device to Someone Else Who Needed to Self Inject? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=yes definitely.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 25, Day 84
0=Not at all
3.3 percentage of participants
4.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 25, Day 84
1=Rarely
2.3 percentage of participants
5.4 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 25, Day 84
2=Occasionally
7.6 percentage of participants
24.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 25, Day 84
3=Often
12.3 percentage of participants
19.3 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 25, Day 84
4=Yes definitely
74.4 percentage of participants
46.3 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. N=participants with evaluable data.

Percentage of participants responding to Device Attributes and Subject Perceptions Questionnaire: How Likely Is It That You Would Use the Device Again - Q26: If Your Doctor Advised You to, How Likely Would You to Be Continue Injecting Regularly With this Device? Participants specified their responses on a 5-point Likert scale: 0=not at all to 4=very likely.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=297 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 26, Day 84
0=Not at all
3.0 percentage of participants
3.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 26, Day 84
1=Usually not
3.0 percentage of participants
7.7 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 26, Day 84
2=Occasionally
9.3 percentage of participants
17.8 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 26, Day 84
3=Likely
11.0 percentage of participants
18.9 percentage of participants
Percentage of Participants Responding to the Device Attribute and Participant Questionnaire, Question 26, Day 84
4=Very likely
73.8 percentage of participants
51.9 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 age clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. The mean age was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=302 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Age Associated With Participant Perception
Cluster 1, Very Satisfied (n=204, 133)
54.3 years
Standard Deviation 12.3
56.0 years
Standard Deviation 13.0
Age Associated With Participant Perception
Cluster 2, Satisfied (n=51, 71)
55.1 years
Standard Deviation 11.9
54.1 years
Standard Deviation 12.5
Age Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
54.0 years
Standard Deviation 14.6
52.7 years
Standard Deviation 13.2

SECONDARY outcome

Timeframe: Day 84

Population: mITT. n=number of participants (male plus female) who reported themselves as being very satisfied, satisfied, or not for the specified treatment arm.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, all male and female participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. The percentage of participants who were male was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=302 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Male Participants Associated With Participant Perception
Cluster 1, Very Satisfied (n=204, 133)
30.9 percentage of male participants
30.1 percentage of male participants
Percentage of Male Participants Associated With Participant Perception
Cluster 2, Satisfied (n=51, 71)
23.5 percentage of male participants
29.6 percentage of male participants
Percentage of Male Participants Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
14.9 percentage of male participants
14.1 percentage of male participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants (male+female) across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants (male+female) who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm and gender.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, all male and female participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. Percentage of participants who were female was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=302 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Female Participants Associated With Participant Perception
Cluster 1, Very Satisfied (n=204, 133)
69.1 percentage of female participants
69.9 percentage of female participants
Percentage of Female Participants Associated With Participant Perception
Cluster 2, Satisfied (n=51, 71)
76.5 percentage of female participants
70.4 percentage of female participants
Percentage of Female Participants Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
85.1 percentage of female participants
85.9 percentage of female participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 social-educational levels and across all 3 clusters who reported themselves as very satisfied, satisfied, or not satisfied. n=participants across all 3 levels reporting themselves as very satisfied, satisfied, or not satisfied for the specified treatment arm.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants in all 3 social-educational level (only reading/writing capacity, high-school level, university level) were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. Percentage of participants with only reading/writing capacity was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=294 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants With Only Reading/Writing Capacity Associated With Participant Perception
Cluster 2, Satisfied (n=51, 70)
45.1 percentage of participants
42.9 percentage of participants
Percentage of Participants With Only Reading/Writing Capacity Associated With Participant Perception
Cluster 1, Very Satisfied (n=203, 132)
35.0 percentage of participants
44.7 percentage of participants
Percentage of Participants With Only Reading/Writing Capacity Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
36.2 percentage of participants
33.7 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 social-educational levels and across all 3 clusters who reported themselves as very satisfied, satisfied, or not satisfied. n=participants at all 3 levels reporting themselves as very satisfied, satisfied, or not satisfied for the specified treatment arm.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants in all 3 social-educational level (only reading/writing capacity, high-school level, university level) were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. Percentage of participants at high school/baccalaureate level was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=294 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants at High School/Baccalaureate Level Associated With Participant Perception
Cluster 1, Very Satisfied (n=203, 132)
48.8 percentage of participants
43.2 percentage of participants
Percentage of Participants at High School/Baccalaureate Level Associated With Participant Perception
Cluster 2, Satisfied (n=51, 70)
37.3 percentage of participants
41.4 percentage of participants
Percentage of Participants at High School/Baccalaureate Level Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
48.9 percentage of participants
47.8 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 social-educational levels and across all 3 clusters who reported themselves as very satisfied, satisfied, or not satisfied. n=participants across all 3 levels reporting themselves as very satisfied, satisfied, or not satisfied for the specified treatment arm.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants in all 3 social-educational level (only reading/writing capacity, high-school level, university level) were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. Percentage of participants at the university level was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=294 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants at University Level Associated With Participant Perception
Cluster 1, Very Satisfied (n=203, 132)
16.3 percentage of participants
12.1 percentage of participants
Percentage of Participants at University Level Associated With Participant Perception
Cluster 2, Satisfied (n=51, 70)
17.6 percentage of participants
15.7 percentage of participants
Percentage of Participants at University Level Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
14.9 percentage of participants
18.5 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. The mean HAD Anxiety Subscale Score was determined for each cluster of participants. Score ranged from 0 to 21. Lower scores indicated better health.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=295 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
HAD Anxiety Subscale Score Associated With Participant Perception
Cluster 1, Very Satisfied (n=203, 132)
6.8 units on a scale
Standard Deviation 4.2
6.4 units on a scale
Standard Deviation 4.5
HAD Anxiety Subscale Score Associated With Participant Perception
Cluster 2, Satisfied (n=51, 71)
7.9 units on a scale
Standard Deviation 3.8
7.4 units on a scale
Standard Deviation 4.0
HAD Anxiety Subscale Score Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
8.3 units on a scale
Standard Deviation 3.7
8.7 units on a scale
Standard Deviation 3.8

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. The mean HAD Depression Subscale Score was determined for each cluster of participants. Score ranged from 0 to 21. Lower scores indicated better health.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=301 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
HAD Depression Subscale Score Associated With Participant Perception
Cluster 1, Very Satisfied (n=203, 133)
5.8 units on a scale
Standard Deviation 3.8
5.0 units on a scale
Standard Deviation 3.9
HAD Depression Subscale Score Associated With Participant Perception
Cluster 2, Satisfied (n=51, 71)
6.6 units on a scale
Standard Deviation 3.9
5.2 units on a scale
Standard Deviation 3.5
HAD Depression Subscale Score Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
7.3 units on a scale
Standard Deviation 4.1
6.7 units on a scale
Standard Deviation 3.6

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. The mean PAM Score was determined for each cluster of participants. Calibrated PAM scale score ranged from 0 to 100.Higher scores indicated more confidence in managing participants' condition and lifestyle.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=293 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
PAM Score Associated With Participant Perception
Cluster 1, Very Satisfied (n=198, 131)
61.6 units on a scale
Standard Deviation 13.1
60.1 units on a scale
Standard Deviation 14.0
PAM Score Associated With Participant Perception
Cluster 2, Satisfied (n=51, 71)
56.6 units on a scale
Standard Deviation 11.5
56.5 units on a scale
Standard Deviation 11.7
PAM Score Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 91)
57.4 units on a scale
Standard Deviation 13.8
55.3 units on a scale
Standard Deviation 11.9

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. The percentage of participants with prior injection experience was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=302 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants With Prior Injection Experience Associated With Participant Perception
Cluster 1, Very Satisfied (n=204, 133)
52.9 percentage of participants
54.9 percentage of participants
Percentage of Participants With Prior Injection Experience Associated With Participant Perception
Cluster 2, Satisfied (n=51, 71)
47.1 percentage of participants
54.9 percentage of participants
Percentage of Participants With Prior Injection Experience Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
70.2 percentage of participants
59.8 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using a multiple correspondence analysis and an ascending hierarchical classification. The percentage of participants with prior self-injection experience was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=302 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants With Prior Self-Injection Experience Associated With Participant Perception
Cluster 1, Very Satisfied (n=204, 133)
31.9 percentage of participants
31.6 percentage of participants
Percentage of Participants With Prior Self-Injection Experience Associated With Participant Perception
Cluster 2, Satisfied (n=51, 71)
15.7 percentage of participants
36.6 percentage of participants
Percentage of Participants With Prior Self-Injection Experience Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
38.3 percentage of participants
31.5 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied , or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. The mean RA Duration was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=302 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
RA Duration Associated With Participant Perception
Cluster 1, Very Satisfied (n=204, 133)
8.6 years
Standard Deviation 8.0
9.7 years
Standard Deviation 9.1
RA Duration Associated With Participant Perception
Cluster 2, Satisfied (n=51, 71)
9.4 years
Standard Deviation 8.2
8.6 years
Standard Deviation 8.1
RA Duration Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
8.9 years
Standard Deviation 8.9
10.3 years
Standard Deviation 8.4

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. The mean DAS28 Score was determined for each cluster of participants. Score ranged from 0 to 9.4. Interpretation: disease activity is low when score ≤3.2, moderate when 3.2\<score≤5.1, or high when score \>5.1, remission when score \<2.6.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=292 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=287 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
DAS28 Score Associated With Participant Perception
Cluster 1, Very Satisfied (n=197, 128)
5.3 units on a scale
Standard Deviation 1.1
5.5 units on a scale
Standard Deviation 1.1
DAS28 Score Associated With Participant Perception
Cluster 2, Satisfied (n=50, 70)
5.4 units on a scale
Standard Deviation 1.3
5.0 units on a scale
Standard Deviation 1.3
DAS28 Score Associated With Participant Perception
Cluster 3, Not Satisfied (n=45, 89)
5.5 units on a scale
Standard Deviation 1.1
5.5 units on a scale
Standard Deviation 1.2

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. Participants' mean Global Assessment of RA Activity was determined for each cluster of participants. VAS scores ranged from 0 (inactive) to 100 mm (extremely active).

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=298 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=294 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant's Global Assessment of RA Activity Associated With Participant Perception
Cluster 2, Satisfied (n=50, 71)
64.7 millimeters on the VAS
Standard Deviation 19.2
57.5 millimeters on the VAS
Standard Deviation 24.0
Participant's Global Assessment of RA Activity Associated With Participant Perception
Cluster 1, Very Satisfied (n=202, 132)
63.5 millimeters on the VAS
Standard Deviation 20.2
62.5 millimeters on the VAS
Standard Deviation 21.4
Participant's Global Assessment of RA Activity Associated With Participant Perception
Cluster 3, Not Satisfied (n=46, 91)
65.7 millimeters on the VAS
Standard Deviation 19.5
68.2 millimeters on the VAS
Standard Deviation 17.6

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. Mean Physician's Global Assessment of RA Activity was determined for each cluster of participants. VAS scores ranged from 0 (inactive) to 100 mm (extremely active).

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=299 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=295 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Physician's Global Assessment of RA Activity Associated With Participant Perception
Cluster 2, Satisfied (n=50, 71)
58.3 millimeters on the VAS
Standard Deviation 18.3
57.4 millimeters on the VAS
Standard Deviation 21.6
Physician's Global Assessment of RA Activity Associated With Participant Perception
Cluster 1, Very Satisfied (n=203, 132)
58.8 millimeters on the VAS
Standard Deviation 18.6
60.8 millimeters on the VAS
Standard Deviation 19.0
Physician's Global Assessment of RA Activity Associated With Participant Perception
Cluster 3, Not Satisfied (n=46, 92)
60.3 millimeters on the VAS
Standard Deviation 16.8
60.1 millimeters on the VAS
Standard Deviation 16.6

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. The mean HAQ-DI Score, assessing the extent of functional ability, was determined for each cluster of participants. Disability score ranged from 0=normal or no difficulty to 3=unable to do. Lower HAQ-DI scores indicated better health.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=300 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
HAQ-DI Score Associated With Participant Perception
Cluster 3, Not Satisfied (n=45, 92)
1.5 units on a scale
Standard Deviation 0.6
1.6 units on a scale
Standard Deviation 0.6
HAQ-DI Score Associated With Participant Perception
Cluster 1, Very Satisfied (n=204, 133)
1.4 units on a scale
Standard Deviation 0.7
1.3 units on a scale
Standard Deviation 0.7
HAQ-DI Score Associated With Participant Perception
Cluster 2, Satisfied (n=51, 71)
1.5 units on a scale
Standard Deviation 0.6
1.3 units on a scale
Standard Deviation 0.6

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters receiving only 1 DMARD who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied , or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, all participants receiving DMARDs (only 1, only 2, only 3, 4 or more DMARDs) were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. Percentage of participants receiving only 1 DMARD was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=163 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=155 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Receiving Only 1 DMARD Associated With Participant Perception
Cluster 3, Not Satisfied (n=25, 44)
54.3 percentage of participants
48.4 percentage of participants
Percentage of Participants Receiving Only 1 DMARD Associated With Participant Perception
Cluster 1, Very Satisfied (n=112, 73)
55.4 percentage of participants
55.3 percentage of participants
Percentage of Participants Receiving Only 1 DMARD Associated With Participant Perception
Cluster 2, Satisfied (n=26, 38)
52.0 percentage of participants
53.5 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters receiving only 2 DMARDs, who reported themselves as very satisfied, satisfied, or not satisfied. n=number of participants receiving only 2 DMARDs who reported themselves as being very satisfied, satisfied , or not satisfied for the specified treatment arm.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, all participants receiving DMARDs (only 1, only 2, only 3, 4 or more DMARDs) were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. Percentage of participants receiving only 2 DMARDs was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=117 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=115 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Receiving Only 2 DMARDs Associated With Participant Perception
Cluster 1, Very Satisfied (n=77, 49)
38.1 percentage of participants
37.1 percentage of participants
Percentage of Participants Receiving Only 2 DMARDs Associated With Participant Perception
Cluster 2, Satisfied (n=21, 26)
42.0 percentage of participants
36.6 percentage of participants
Percentage of Participants Receiving Only 2 DMARDs Associated With Participant Perception
Cluster 3, Not Satisfied (n=19, 40)
41.3 percentage of participants
44.0 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters receiving only 3 DMARDs who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants receiving only 3 DMARDs who reported themselves as very satisfied, satisfied , or not satisfied for the specified treatment arm.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, all participants receiving DMARDs (only 1, only 2, only 3, 4 or more DMARDs) were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. Percentage of participants receiving only 3 DMARDs was determined for each cluster of participants.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=14 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=24 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Percentage of Participants Receiving Only 3 DMARDs Associated With Participant Perception
Cluster 1, Very Satisfied (n=9, 10)
4.5 percentage of participants
7.6 percentage of participants
Percentage of Participants Receiving Only 3 DMARDs Associated With Participant Perception
Cluster 2, Satisfied (n=3, 7)
6.0 percentage of participants
9.9 percentage of participants
Percentage of Participants Receiving Only 3 DMARDs Associated With Participant Perception
Cluster 3, Not Satisfied (n=2, 7)
4.3 percentage of participants
7.7 percentage of participants

SECONDARY outcome

Timeframe: Day 84

Population: mITT. Number of participants analyzed (N)=total number of participants across all 3 clusters who reported themselves as being very satisfied, satisfied, or not satisfied. n=number of participants who reported themselves as being very satisfied, satisfied, or not satisfied for the specified treatment arm and cluster.

Participant perception was assessed with the 26 questions in the Device Attribute and Participant Questionnaire. Based on the scores assigned to the 26 questions, participants were grouped into 3 clusters (Cluster 1=very satisfied, Cluster 2=satisfied, Cluster 3=not satisfied) using multiple correspondence analysis and ascending hierarchical classification. Mean participant satisfaction was determined for each cluster of participants. Satisfaction was scored on a 10-point scale: 0=totally dissatisfied to 10=totally satisfied. Higher scores indicated greater satisfaction.

Outcome measures

Outcome measures
Measure
Enbrel 50 mg Autoinjector
n=302 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=296 Participants
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Participant Satisfaction at Endpoint Associated With Participant Perception
Cluster 1, Very Satisfied (n=204, 133)
9.0 units on a scale
Standard Deviation 1.9
8.0 units on a scale
Standard Deviation 2.5
Participant Satisfaction at Endpoint Associated With Participant Perception
Cluster 2, Satisfied (n=51, 71)
8.1 units on a scale
Standard Deviation 1.7
8.2 units on a scale
Standard Deviation 1.6
Participant Satisfaction at Endpoint Associated With Participant Perception
Cluster 3, Not Satisfied (n=47, 92)
5.5 units on a scale
Standard Deviation 2.8
5.3 units on a scale
Standard Deviation 2.4

Adverse Events

Enbrel 50 mg Autoinjector

Serious events: 18 serious events
Other events: 203 other events
Deaths: 0 deaths

Enbrel 50 mg Prefilled Syringe

Serious events: 9 serious events
Other events: 201 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Enbrel 50 mg Autoinjector
n=325 participants at risk
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 participants at risk
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Blood and lymphatic system disorders
Anaemia
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Cardiac disorders
Palpitations
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Cardiac disorders
Sinus bradycardia
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Eye disorders
Retinal vein thrombosis
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders
Abdominal pain upper
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders
Diarrhoea
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders
Gastric ulcer
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders
Intestinal haemorrhage
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
General disorders
Pain
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
General disorders
Pyrexia
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Bronchitis
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Cystitis
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.64%
2/313 • Number of events 2
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Erysipelas
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Groin abscess
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Herpes zoster
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Infection
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Respiratory tract infection
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Sinusitis
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Injury, poisoning and procedural complications
Complication of device insertion
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Investigations
Heart rate irregular
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Musculoskeletal and connective tissue disorders
Bursitis
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Musculoskeletal and connective tissue disorders
Muscular weakness
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Musculoskeletal and connective tissue disorders
Osteoarthritis
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Nervous system disorders
Cerebral infarction
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Nervous system disorders
Cervical root pain
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Nervous system disorders
Dizziness
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 2
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Nervous system disorders
Syncope vasovagal
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Renal and urinary disorders
Renal failure
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Reproductive system and breast disorders
Nipple disorder
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Skin and subcutaneous tissue disorders
Rash pruritic
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Surgical and medical procedures
Breast cyst excision
0.00%
0/325
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.32%
1/313 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Surgical and medical procedures
Knee arthroplasty
0.31%
1/325 • Number of events 1
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.00%
0/313
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.

Other adverse events

Other adverse events
Measure
Enbrel 50 mg Autoinjector
n=325 participants at risk
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using autoinjector
Enbrel 50 mg Prefilled Syringe
n=313 participants at risk
Enbrel 50 mg once weekly subcutaneously for 12 Weeks using prefilled syringe
Gastrointestinal disorders
Nausea
2.2%
7/325 • Number of events 8
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
2.9%
9/313 • Number of events 32
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
General disorders
Injection site erythema
7.7%
25/325 • Number of events 61
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
9.3%
29/313 • Number of events 62
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
General disorders
Injection site haematoma
4.6%
15/325 • Number of events 19
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
1.9%
6/313 • Number of events 6
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
General disorders
Injection site haemorrhage
3.1%
10/325 • Number of events 14
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
1.9%
6/313 • Number of events 6
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
General disorders
Injection site irritation
0.92%
3/325 • Number of events 3
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
3.2%
10/313 • Number of events 20
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
General disorders
Injection site pain
6.2%
20/325 • Number of events 43
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
4.2%
13/313 • Number of events 30
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
General disorders
Injection site rash
0.92%
3/325 • Number of events 6
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
2.2%
7/313 • Number of events 9
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
General disorders
Injection site reaction
14.2%
46/325 • Number of events 97
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
17.6%
55/313 • Number of events 173
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Bronchitis
1.8%
6/325 • Number of events 7
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
3.8%
12/313 • Number of events 13
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Influenza
2.8%
9/325 • Number of events 9
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
2.6%
8/313 • Number of events 8
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Nasopharyngitis
6.8%
22/325 • Number of events 22
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
8.3%
26/313 • Number of events 28
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Upper respiratory tract infection
2.8%
9/325 • Number of events 9
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
0.64%
2/313 • Number of events 2
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Infections and infestations
Urinary tract infection
1.5%
5/325 • Number of events 5
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
2.9%
9/313 • Number of events 10
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
1.8%
6/325 • Number of events 7
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
3.2%
10/313 • Number of events 10
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Nervous system disorders
Headache
2.8%
9/325 • Number of events 15
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
1.9%
6/313 • Number of events 12
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders
Cough
0.92%
3/325 • Number of events 3
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
2.6%
8/313 • Number of events 9
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
Skin and subcutaneous tissue disorders
Pruritus
1.8%
6/325 • Number of events 6
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.
2.9%
9/313 • Number of events 19
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer, Inc.

Phone: 1-800-718-1021

Results disclosure agreements

  • Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
  • Publication restrictions are in place

Restriction type: OTHER